Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136545) titled 'A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Taipei Veterans General Hospital, Taiwan
Condition:
HNSCC
Intervention:
Drug: HCB101
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 1, 2025
Target Sample Size: 50
Countries of Recruitment:
Taiwan
To kn...